Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05487846 · ClinicalTrials.gov registry record · NA

Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation

A NA study of Metastatic Prostate Carcinoma and Stage IV Prostate Cancer AJCC v8, sponsored by Thomas Jefferson University.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT05487846: Recruiting NA study of Metastatic Prostate Carcinoma and Stage IV Prostate Cancer AJCC v8, sponsored by Thomas Jefferson University.

NCT05487846 is a NA study of Metastatic Prostate Carcinoma and Stage IV Prostate Cancer AJCC v8 that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 120 participants, roughly in line with the 129-participant average among 37 other Metastatic Prostate Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05487846, a NA study of Metastatic Prostate Carcinoma and Stage IV Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by Thomas Jefferson University.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

This clinical trial evaluates whether having a trained peer navigator helps African American men with prostate cancer that has spread to other parts of the body (metastatic) understand and navigate the genetic testing process better than not having a peer navigator. Genetic testing for men with prostate cancer is very important for making treatment and management decisions. However, understanding the risks, benefits, and steps of genetic counseling and testing can be very challenging for patients. African American men are especially less likely to participant in genetic testing due to lack of awareness or understanding, cultural beliefs, finances, or mistrust of the healthcare system. A peer navigator, someone who helps a patient through the information and the process, may be helpful to some men. This study evaluates whether having a peer navigator throughout the genetic evaluation process helps patients understand and engage in the process more.

Primary Outcome

Compared between randomized study groups. Tested using a chi-square test. Summarized between study groups in tables with descriptive statistics (e.g.'s, means and standard deviations if continuous, frequencies and percentages if discrete) with 95% confidence intervals and also graphically in data plots at each time they are assessed along with changes in responses over time.

Interventions

  • OTHER Survey Administration
  • OTHER Best Practice
  • OTHER Genetic Counseling
  • BEHAVIORAL Patient Navigation

Study Locations (1)

Pennsylvania

  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-01-01
Est. Completion 2026-05-31
Phase NA
Thomas Jefferson University

292 total trials

What NCT05487846 shows while recruiting

NCT05487846 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 129-participant average among 37 other Metastatic Prostate Carcinoma trials with a reported enrollment target.

The record links to 3 conditions, with Metastatic Prostate Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Survey Administration is the first listed.

NCT05487846 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05487846 about?

NCT05487846 is a clinical study titled "Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation". This clinical trial evaluates whether having a trained peer navigator helps African American men with prostate cancer that has spread to other parts of the body (metastatic) understand and navigate the genetic testing process better than not having a peer navigator. Genetic testing for men with pros...

What is the current status of trial NCT05487846?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-01-01. Estimated completion is 2026-05-31.

What conditions does trial NCT05487846 study?

This clinical trial studies the following conditions: Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8.

What interventions are being tested in trial NCT05487846?

The interventions under investigation include: Survey Administration (OTHER), Best Practice (OTHER), Genetic Counseling (OTHER), Patient Navigation (BEHAVIORAL).

Who is sponsoring clinical trial NCT05487846?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05487846 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05487846's enrollment target sits among peer trials

120 9th of 37 higher than 28 of 37 other Metastatic Prostate Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05487846, the US trial registry maintained by the National Library of Medicine. NCT05487846 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.